Privi Speciality Chemicals Limited has released its investor presentation for the quarter ended June 30, 2026 (Q1 FY27). The presentation highlights a strong start to the year with 20.01% YoY growth in total income to ₹681.42 Cr and a 35.97% YoY growth in Net Profit to ₹84.21 Cr. It also outlines the company’s strategic priorities and growth outlook, including expansion projects set for commercial operations in the second half of 2028.
Privi Speciality Chemicals Presents Q1 FY27 Performance and Strategy
Privi Speciality Chemicals Limited has submitted its investor presentation for the first quarter of FY27, ending June 30, 2026. The document details the company’s financial and operational review, underscoring a resilient business model and disciplined execution.
Key Financial Highlights
During Q1 FY27, Privi Speciality Chemicals reported a total income of ₹681.42 Crore, marking a significant 20.01% year-on-year growth. The company also achieved an EBITDA of ₹167.47 Crore, up by 18.73% year-on-year. Net Profit for the quarter stood at ₹84.21 Crore, reflecting a robust 35.97% year-on-year increase. These positive results were attributed to broad-based demand across domestic and export markets.
Operational Resilience and Strategic Outlook
The company emphasized its continued resilience despite global headwinds and highlighted its diversified geographic presence as a factor supporting market stability. Privi Speciality Chemicals has not experienced operational or supply chain disruptions, reinforcing its structural strength. Looking ahead, new products are expected to expand the addressable market and contribute to future growth. The presentation also confirmed that expansion projects are progressing as planned, with commercial operations anticipated in the second half of 2028. The company maintains a strong balance sheet, healthy cash flows, and a clear strategic roadmap, positioning it well for the future.
Future Vision: 5k | 1k Milestone
Privi Speciality Chemicals is marching towards its vision of achieving ₹5,000 Crore revenue and ₹1,000 Crore EBITDA by FY29-30, representing more than a 2x growth. EBITDA margins are projected to sustain above 20%, driven by continued operational efficiency and an enhanced product mix. Key initiatives supporting this vision include existing product expansion, new product innovation with items like Maltol, Ethyl Maltol, Renewable Cyclopentanone, Furfural, and over 40+ products under PRIGIV.
Strategic Initiatives and Competitive Advantages
The company’s growth strategy is underpinned by several key levers, including its China +1 Strategy to diversify supply chains, state tax incentives for CAPEX, efficient working capital management, existing product expansion, new product innovation, and gross margin expansion. A proposed scheme of amalgamation involving Privi Fine Sciences Private Limited (PFSPL) and Privi Biotechnologies Private Limited (PBPL) with Privi Speciality Chemicals Limited (PSCL) aims to create synergistic growth and enhance agility through integration. Key rationales include a diverse product portfolio, innovation-driven research, biotech-focused R&D, and a green science advantage, aligning with a vision for sustainable, nature-like aroma chemicals.
Privi Speciality Chemicals also highlighted its competitive advantages, such as backward integration with in-house CST processing, robust manufacturing facilities, and strong R&D capabilities. The company’s journey shows consistent growth, from starting manufacturing aroma chemicals in 1993 to crossing significant turnover milestones and expanding its global presence with facilities and distribution networks across multiple continents.
Source: BSE
